- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00388245
Revascularization in Heart Failure Trial - REHEAT 2
Myocardial Revascularization in Patients With Ischemic Cardiomyopathy: a Comparison Between Percutaneous Coronary Intervention and Coronary Artery Bypass Surgery
Study Overview
Status
Intervention / Treatment
Detailed Description
Heart failure constitutes one of basic problems of contemporary cardiology. It is most commonly caused by ischaemic heart disease, which as an etiologic factor, has a negative impact on prognosis. On the other hand, decreased left ventricular ejection fraction is the most important prognostic factor in patients with ischaemic heart disease. Annual mortality among patients with ejection fraction below 35% accounts for 17%, and in a group with ejection fraction below 25% reaches 24%. Most of multicenter studies (e.g. ARTS, BARI, ERACI) comparing results of percutaneous and surgical revascularisation in ischemic heart disease pertain to patients with normal or minimally decreased left ventricular ejection fraction, excluding patients with left ventricular ejection fraction lower than 35%. Current medical standards indicate the surgical way as a method of choice in treatment of patients with ischemic cardiomyopathy.
In early nineties the procedures of percutaneous angioplasty in patients with depressed left ventricular function were connected with comparable to CABG risk of death (5-10%).
The intensive progress of percutaneous procedures contributed PCI is competitive method of revasularization to CABG. Our knowledge about the efficacy of above mentioned methods in patients with ischemic heart failure is scarce until now. It was proved, that patients with viable myocardium assessed in dobutamine stress echocardiography or MRI benefit mostly from myocardial revascularization. Repeat revascularization during follow up occurred more frequently in patients after PCI, so that introduction of coronary stents, especially drug eluting stents (DES) could significantly improve the clinical outcome after PCI procedures. The administration of antiplatelet drugs (IIb/IIIa platelet receptor inhibitors) have considerably improved the short and long-term results of PCI so that it is interesting if they could have beneficial effect on clinical outcome of patients with ischemic heart failure. In the field of cardiac surgery the method of left ventricle reconstruction in patients with ischemic cardiomyopathy (STICH Trial) seems to be promising.
Therefore, the comparison of innovative methods of percutaneous and surgical revascularization may influence current medical standards concerning patients with ischemic heart disease.
Study Type
Enrollment
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Pawel E Buszman, Prof
- Phone Number: +48 32 252 72 12
- Email: pbuszman@ka.onet.pl
Study Contact Backup
- Name: Iwona Szkrobka, MD
- Phone Number: +48 602 457 602
- Email: wilenka@wp.pl
Study Locations
-
-
-
Warsaw, Poland, 02-507
- Central Clinic Hospital
-
Principal Investigator:
- Robert J Gil, Prof
-
Wroclaw, Poland, 50-981
- Military Clinic Hospital
-
Principal Investigator:
- Piotr Ponikowski, Prof
-
-
Silesia
-
Katowice, Silesia, Poland, 40-635
- University School of Silesia, 1-st Department of Cardiosurgery
-
Principal Investigator:
- Andrzej Bochenek, Prof
-
Katowice, Silesia, Poland, 40-635
- University School of Silesia, 3-rd Department of Cardiology, Coronary Care Unit
-
Principal Investigator:
- Pawel E Buszman, Prof
-
Sub-Investigator:
- Iwona Szkrobka, MD
-
Principal Investigator:
- Michal Tendera, Prof
-
Sub-Investigator:
- Aleksander Zurakowski, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- symptomatic coronary artery disease (angina CCS class 1)
- left ventricle ejection fraction <40%
- coronary artery lesions suitable for percutaneous or surgical myocardial revascularisation
- evidence for viability of the myocardium
- written inform consent for the study
Exclusion Criteria:
- age <18 years
- acute myocardial infarct with ST elevation within 30 days
- concomitant congenital heart disease
- mitral regurgitation required surgical intervention
- history of bleeding diathesis, coagulopathy or abnormal bleeding within the previous 30 days.
- major surgery within the previous 6 weeks
- stroke or transient ischemic attack (TIA) within the previous 6 weeks
- history of hemorrhagic stroke
- uncontrolled hypertension
- chronic renal insufficiency with creatinine >2.0 mg/dl
- platelet count <100.000/mm3
- hematocrit <30%
- PT >1,2 times control
- positive pregnancy test
- any disease that may shorten the life expectancy of the patient
- the patient is currently participating in another research study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
LV ejection fraction after 1 year since the index procedure
|
Secondary Outcome Measures
Outcome Measure |
---|
in-hospital and 30 day major adverse events (MAE) and major adverse cardiovascular events (MACE) defined as: death, AMI, stroke, acute heart failure, re-CABG, re-PTCA;
|
major adverse coronary and cerebrovascular events during 1 year follow-up (MACCE): death, repeat revascularisation, AMI, unstable angina, heart transplantation, heart failure stroke;
|
long term survival;
|
severity of angina, exercise and functional capacity along with assessment of quality of life in one year observation.
|
Collaborators and Investigators
Investigators
- Study Director: Pawel E Buszman, Prof, 3-rd Division of Cardiology, University School of Silesia, Poland
- Study Chair: Michal Tendera, Prof, 3-rd Division of Cardiology, University School of Silesia, Poland
- Principal Investigator: Andrzej Bochenek, Prof, 1-st Division of Cardiosurgery, University School of Silesia, Poland
- Principal Investigator: Robert J Gil, Prof, Invasive Cardiology Department, Central Clinic Hospital, Warsaw, Poland
- Principal Investigator: Piotr Ponikowski, Prof, Heart Disease Department, Military Clinic Hospital, Wroclaw, Poland
Publications and helpful links
General Publications
- Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A, Bonnier JJ, Schonberger JP, Buller N, Bonser R, Disco C, Backx B, Hugenholtz PG, Firth BG, Unger F. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol. 2005 Aug 16;46(4):575-81. doi: 10.1016/j.jacc.2004.12.082.
- Scholz KH, Dubois-Rande JL, Urban P, Morice MC, Loisance D, Smalling RW, Figulla HR. Clinical experience with the percutaneous hemopump during high-risk coronary angioplasty. Am J Cardiol. 1998 Nov 1;82(9):1107-10, A6. doi: 10.1016/s0002-9149(98)00566-9.
- Shawl FA, Quyyumi AA, Bajaj S, Hoff SB, Dougherty KG. Percutaneous cardiopulmonary bypass-supported coronary angioplasty in patients with unstable angina pectoris or myocardial infarction and a left ventricular ejection fraction < or = 25%. Am J Cardiol. 1996 Jan 1;77(1):14-9. doi: 10.1016/s0002-9149(97)89127-8.
- Van Belle E, Blouard P, McFadden EP, Lablanche JM, Bauters C, Bertrand ME. Effects of stenting of recent or chronic coronary occlusions on late vessel patency and left ventricular function. Am J Cardiol. 1997 Nov 1;80(9):1150-4. doi: 10.1016/s0002-9149(97)00631-0.
- Bax JJ, Poldermans D, Elhendy A, Cornel JH, Boersma E, Rambaldi R, Roelandt JR, Fioretti PM. Improvement of left ventricular ejection fraction, heart failure symptoms and prognosis after revascularization in patients with chronic coronary artery disease and viable myocardium detected by dobutamine stress echocardiography. J Am Coll Cardiol. 1999 Jul;34(1):163-9. doi: 10.1016/s0735-1097(99)00157-6.
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0213/P01/2006/31
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Heart Disease
-
Genzyme, a Sanofi CompanyTerminatedIschemic Heart Disease | Ischemic Cardiomyopathy | Ischemic Heart FailureBelgium, France, Germany, Italy, Switzerland, United Kingdom
-
University of AlbertaRecruitingCoronary Artery Disease | Stable Ischemic Heart Disease | Beta-blocker TherapyCanada
-
Gerencia de Atención Primaria, MadridServicio Canario de Salud; Avedis Donabedian Research InstituteCompletedIschemic Heart Disease ChronicSpain
-
Michael SekelaCompletedChronic Ischemic Heart DiseaseUnited States
-
Cardiocentro TicinoTerminatedChronic Ischemic Heart DiseaseSwitzerland
-
Rigshospitalet, DenmarkNot yet recruitingChronic Ischemic Heart DiseaseDenmark
-
University of PecsCompleted
-
The University of Texas Health Science Center,...National Heart, Lung, and Blood Institute (NHLBI); Cardiovascular Cell Therapy...CompletedIschemic Cardiomyopathy | Left Ventricular Dysfunction | Angina | Chronic Ischemic Heart DiseaseUnited States
-
Affiliated Hospital to Academy of Military Medical...Ivy Institute of Stem Cells Co. LtdUnknownHeart Failure | Angina | Chronic Ischemic Heart DiseaseChina
-
University of EdinburghUnknown
Clinical Trials on Percutaneous Coronary Intervention
-
Mid and South Essex NHS Foundation TrustImperial College LondonRecruitingStable Angina | Chronic Total Occlusion of Coronary ArteryUnited Kingdom
-
University Hospital, SaarlandCompletedAcute Myocardial InfarctionGermany
-
Nanjing First Hospital, Nanjing Medical UniversityCompletedCoronary Artery DiseaseChina
-
University Hospital of PatrasCompletedCoronary Artery Bypass SurgeryGreece
-
Yonsei UniversityUnknownCoronary Artery Disease | Stable Angina | Unstable AnginaKorea, Republic of
-
ECRI bvBoston Scientific Corporation; Philips HealthcareActive, not recruitingLeft Main Coronary Artery StenosisSpain, United Kingdom, Italy
-
Herlev and Gentofte HospitalUnknownCoronary Heart Disease | Ischemic Heart Disease | Stable AnginaDenmark
-
RobocathCompletedCoronary Artery Disease | Percutaneous Coronary InterventionFrance, Belgium, Luxembourg, Netherlands
-
University College, LondonNational Institute for Cardiovascular Outcomes Research; British Cardiovascular... and other collaboratorsCompletedPercutaneous Coronary InterventionUnited Kingdom
-
Niels Ramsing HolmJohnson & JohnsonUnknown